CLINICAL TRIALS PROFILE FOR DANICOPAN
✉ Email this page to a colleague
Clinical Trials for Danicopan
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Achillion, a wholly owned subsidiary of Alexion | Phase 2 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Achillion Pharmaceuticals | Phase 2 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Alexion Pharmaceuticals | Phase 2 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Danicopan
Condition Name
Clinical Trial Locations for Danicopan
Trials by Country
Clinical Trial Progress for Danicopan
Clinical Trial Phase
Clinical Trial Sponsors for Danicopan
Sponsor Name